



Antibiogram of Gram-negative bacilli (GNB) Isolated from Urinary Tract Infection (UTI)- with a Special Reference to Detection of Amp C β -lactamase Producing Gram-negative bacilli Causing UTI

Anjali Sunil Datta Jog

Assistant Lecturer, Department of FMT, D.Y. Patil Medical College, Kolhapur, Maharashtra, India.

ABSTRACT

Introduction: Urinary tract infection (UTI) remains one of the most common causes of morbidity in the general population. Wide variety of organisms are implicated in its aetiology, gram-negative bacilli (GNB) being most common. UTI is treated with a variety of broad-spectrum antibiotics. Resistance to antibiotics is increasing nowadays. Gram-negative bacilli confer resistance to β -lactam antibiotics by producing enzymes like Extended-spectrum β – lactamase and Amp C β – lactamase. The present study was carried out with the aim and objectives to isolate and identify GNB causing UTI and to prepare antibiogram of these isolates. The study also includes to find out the prevalence of Amp C β – lactamase producing GNB causing UTI.

Materials and Methods: The urine samples obtained from patients having suspected urinary tract infection were processed to isolate and identify the causative organism. Antibiotic susceptibility testing was done by Kirby Bauer Disk Diffusion method for gram-negative urinary isolates in patients with significant bacteriuria. Clinical Laboratory Standards Institute (CLSI) guidelines were followed during the interpretation of results. GNB showing resistance to 3rd generation cephalosporins and resistance to cefoxitin were subjected to Amp C Disk Test to detect Amp C β – lactamase producing GNB. Minimum Inhibitory Concentration (MIC) for ceftazidime was tested for these isolates.

Results: Total of 288 samples from patients with suspected UTI were processed. 214 samples were culture positive. Out of which 167 samples showed significant bacteriuria (78.03%). Gram-negative bacilli isolated were 74.85%. All GNB showed reduced susceptibility to 3rd generation cephalosporins. They were susceptible to amikacin, nitrofurantoin, imipenem, meropenem. *Pseudomonas* isolates showed resistance to imipenem and meropenem. Prevalence of Amp C β – lactamase producing GNB was 21.6%.

Conclusion: Gram-negative bacilli producing UTI were 74.85%. These isolates showed resistance to 3rd generation cephalosporins. They were susceptible to amikacin, nitrofurantoin, imipenem, meropenem. *Pseudomonas* isolates were resistant to imipenem and meropenem. Prevalence of Amp C β – lactamase producing GNB was 21.6%.

Key Words: Urinary tract infection (UTI), Gram-negative bacilli (GNB), Antibiotic Susceptibility Testing (AST), Drug resistance, Amp C β -lactamase, Amp C Disk Test

INTRODUCTION

Urinary tract infection may be caused by the invasion of bacteria and their multiplication in urinary tract¹. Kass (1956) gave a criterion of active bacterial infection of the urinary tract according to which a count exceeding 10^5 organisms / ml denotes significant bacteriuria and indicates active UTI. Contamination accounts for 10^4 organisms/ml and also counts less than 10^3 organisms/ml¹. UTI covers a broad range of clinical entities that differ in clinical presentation, degree of tissue invasion, antibiotic requirement and epidemiological

settings². Patients with UTI may present with a wide range from asymptomatic infection to pyelonephritis². The common symptoms of UTI are urgency and frequency of micturition along with that patient may have pain and lower abdominal discomfort. The commonest condition is cystitis, due to infection of bladder with the uropathogenic bacterium, of which *E.coli* is the most common³. Other organisms are *Staphylococci saprophyticus* or in hospital-acquired infections *Klebsiella spp.*, *Proteus mirabilis*, other coliforms, *Pseudomonas aeruginosa*, or *Enterococcus faecalis*³. Diabetic patients and immuno-compromised patients may get

Corresponding Author:

Dr. Anjali Sunil Datta Jog, 212/4 E Ward, Plot no. 9, 'Swaragandha', Nakshtra Park, Kadamwadi Road, Kolhapur, Maharashtra, India;
Email: anjali.jog@yahoo.in

ISSN: 2231-2196 (Print)

ISSN: 0975-5241 (Online)

Received: 24.05.2020

Revised: 12.06.2020

Accepted: 02.07.2020

Published: 08.08.2020

candida infection³. The gram-positive organisms that can cause UTI to include *Staphylococcus aureus*, *Coagulase Negative Staphylococci*, *Streptococcus faecalis*, *Streptococcus pyogenes* and other streptococci⁴. Urinary tract infection is a common problem faced in practice. It accounts for 35% of all hospital-acquired infections and 2nd most common cause of bacteremia in indoor cases^{5,6}.

UTI is often treated with different broad-spectrum antibiotics. Antimicrobial resistance to third-generation cephalosporins is increasing. Resistance to β -lactam antibiotics is through the production of the β -lactamase enzyme that breaks down the structure of β -lactam ring of penicillin and other antimicrobials of similar structure. In mid 1980's a new type of β -lactamase was produced that could hydrolyse 3rd generation cephalosporins called as Extended-spectrum β -lactamase. (ESBL)⁷. The activity of the majority of ESBL's is inhibited by β -lactamase inhibitors like clavulanic acid, sulbactam, tazobactam. Amp C β -lactamases are cephalosporinases that are poorly inhibited by clavulanic acid. Amp C β -lactamases are presumed to be plasmid-mediated and chromosomal or inducible^{8,9}.

Increased emergence of antimicrobial resistance in uropathogenic probably due to empirical administration of antibacterial therapy, even before the availability of urine culture reports is a major concern world-wide¹⁰.

By considering all above points, the present study was carried out in our hospital to find out antibiotic sensitivity of gram-negative bacilli causing UTI and also to find out the prevalence of Amp C β -lactamase producing gram-negative bacilli isolated from urine samples of patients with urinary tract infections.

Aim

To study antimicrobial sensitivity of gram-negative bacilli isolated from urine in patients with urinary tract infections and also to find out the prevalence of Amp C β -lactamase producing gram-negative bacilli (GNB) in UTI.

Objectives

- 1) To isolate and identify gram-negative bacilli from urine samples collected from patients with UTI.
- 2) To evaluate the antimicrobial sensitivity pattern of gram-negative bacilli (GNB) isolated from urine samples from patients of UTI.
- 3) To find the prevalence of Amp C β -lactamase producing GNB from urine samples in these patients.

MATERIAL AND METHODS

This study was done in Dr D.Y. Patil Medical College, Hospital and Research Institute, Kolhapur. Duration of the study was for a period from 1st January 2015 to 30th September

2015. Ethical clearance was taken from the institutional ethics committee. Informed consent was taken from all the patients who participated in the study. The study was done with inclusion and exclusion criteria as follows-

Inclusion criteria

- 1) The study includes all the patients having suspected urinary tract infection.
- 2) Gram-negative bacilli isolated from urine samples with significant bacteriuria.

Exclusion criteria

- 1) Urine samples with insignificant bacteriuria.
- 2) Urine samples of significant bacteriuria from which gram-positive bacteria and *Candida* spp. were isolated.

Collection of samples- Urine samples were collected from the patients, with suspected urinary tract infection referred for urine culture by clinicians. Mid-stream urine samples were collected in wide mouth sterile bottle by clean catch technique. In women, the periurethral area and perineum was cleaned with soap and water using forward to back technique. In male patients, cleaning of urethral meatus before voiding urine was done.

Processing of samples was done without delay. Samples were plated on Blood Agar, Mac-Conkey Agar and incubated at 37°C for 24 hours. Urine culture was done using semi-quantitative culture technique using standard calibrated loop². Gram staining was done. Gram-negative bacilli were identified by standard bacteriological techniques. Culture showing $\geq 10^5$ organisms was reported as significant bacteriuria.

Antimicrobial susceptibility testing of these gram-negative bacilli was performed by Kirby-Bauer Disk diffusion method using Mueller Hinton Agar (MHA). Antibiotics disks (from Hi-Media Mumbai) were used. Antibiotics used - Ceftazidime (30 μ g), Ceftriaxone (30 μ g), Cefoxitin (30 μ g), Cefotaxime (30 μ g), Ceftazidime-clavulanic acid (30/10 μ g), Piperacillin-tazobactam (100/10 μ g), Amikacin (30 μ g), Nitrofurantoin (300 μ g), Ciprofloxacin (5 μ g), Gentamicin (10 μ g), Imipenem (10 μ g), Meropenem (30 μ g). Results were recorded as per guidelines by Clinical Laboratory Standards Institute (CLSI)¹¹.

GNB showing resistance to 3rd generation cephalosporins were further tested for Amp C β -lactamase production. Presumptive identification Amp C β -lactamase producers was done by-

- 1) Isolates showing decreased susceptibility to combination disk of Ceftazidime and β -lactamase inhibitors like clavulanic acid.
- 2) Cefoxitin resistance¹²- Lawn culture of test isolate (0.5 McFarland Std.) was done on Mueller Hinton Agar plate. Cefoxitin disk (30 μ g) was placed on inoculated MHA plate. Overnight incubation of plate at 35°C was done. Isolates showing zone of inhibition of Cefoxitin

disk less than 18 mm were considered as screen positive.

Confirmation of Amp C β -lactamase producing isolates was done using Amp C Disk test^{12,13}.

Amp C Disk Test^{12,13,14}- A lawn culture of std. strain *E.coli* ATCC 25922 was done on MHA plate. A sterile filter paper disk (6mm in diameter) was moistened with sterile distilled water (20 μ l). This filter paper disk was inoculated with several colonies of the test organism. A Cefoxitin disk (30 μ gm) was placed on the inoculated plate. Above mentioned moistened filter paper disk was placed beside Cefoxitin disk (Almost touching) The plate was incubated overnight at 37°C. Results were interpreted as follows-

- 1) Positive- If there is flattening or indentation of the zone of inhibition of Cefoxitin in the vicinity of test disk, the result is taken as positive.
- 2) Negative- Result is interpreted as negative if there is an undistorted zone of inhibition of Cefoxitin disk.

Hi Comb MIC Test- Minimum Inhibitory Concentration (MIC) was tested for all Amp C β -lactamase producing isolates using Hi Comb MIC strips of Ceftazidime. (*E.coli* ATCC 25922 was used as negative control)

Data analysis was done by MS -Excel computer language. (Data analysis tool park option). MIC strips and antibiotic disks manufactured by Hi Media Mumbai were used.

Results- Total 288 urine samples obtained from the patients of suspected UTI, were processed in the present study.

Table 1: Prevalence of growth of organisms in urine culture

Total no. of urine samples	Positive Growth	No Growth
288	214 (74.31%)	74 (25.69%)

Out of 214 culture-positive samples, 167 samples showed significant bacteriuria.




Figure 1: Sex wise distribution of patients with Urinary Tract Infection.

Out of 167 samples of significant bacteriuria, gram-negative bacilli were 125 in number (74.85%), gram-positive bacterial isolates were 38 (22.75%) and candida 4 isolates (2.40%).




Figure 2: Distribution of bacterial isolates of UTI.

Table 2: Distribution of gram-negative bacilli in UTI

Name of bacteria(n=125)	Number of isolates	Percentage
<i>Escherichia coli</i>	83	66.4%
<i>Citrobacter spp.</i>	19	15.2%
<i>Klebsiella pneumoniae</i>	09	7.2%
<i>Pseudomonas aeruginosa</i>	11	8.8%
<i>Proteus spp.</i>	03	2.4%
Total isolates	125	100%

Table 3: Antibiotic sensitivity pattern of GNB isolated from UTI

Name of antibiotic	<i>E. coli</i> (n=83)	<i>Citrobacter spp.</i> (n=19)	<i>Klebsiella pneumoniae</i> (n=09)	<i>P.aeruginosa</i> N=11	<i>Proteus spp.</i> (n=03)
Amikacin	66 (79.51%)	16 (84.21%)	7 (77.78%)	7(63.63%)	2 (66.67%)
Ceftazidime	56 (67.45%)	10 (52.63%)	3(33.33%)	6(54.55%)	1 (33.33%)
Ceftriaxone	50 (60.24%)	12 (63.16%)	4(44.44%)	6(54.55%)	1 (33.33%)
Cefotaxime	52 (62.65%)	11 (57.89%)	3(33.33%)	7(63.63%)	2 (66.67%)

Table 3: (Continued)

Name of antibiotic	<i>E. coli</i> (n=83)	<i>Citrobacter</i> spp. (n=19)	<i>Klebsiella pneumoniae</i> (n=09)	<i>P.aeruginosa</i> N=11	<i>Proteus</i> spp. (n=03)
Ceftazidime- clavulanic acid	63 (75.90%)	11 (57.89%)	6(66.67%)	8(72.73%)	2 (66.67%)
Piperacillin-tazobactam	68 (81.92%)	11 (57.89%)	7(77.78%)	8(72.73%)	1 (33.33%)
Imipenem	79 (95.18%)	15 (78.95%)	7(77.78%)	2(18.18%)	2 (66.67%)
Meropenem	76 (91.57%)	14 (73.68%)	8(88.89%)	3(27.27%)	3 (100%)
Nitrofurantoin	67 (80.72%)	16 (84.21%)	7(77.78%)	6(54.55%)	2 (66.67%)
Ciprofloxacin	62 (74.70%)	14 (73.68%)	6(66.67%)	6(54.55%)	2 (66.67%)
Gentamicin	51 (61.45%)	12 (63.16%)	6(66.67%)	7(63.63%)	2 (66.67%)

Table 4: Gram negative isolates positive for Amp C β -lactamase production by confirmatory test.

Name of bacteria	Number of isolates	Percentage
<i>Escherichia coli</i> (n=83)	17	20.48%
<i>Citrobacter</i> spp.(n=19)	6	31.58%
<i>Klebsiella pneumoniae</i> (n=09)	3	33.33%
<i>Pseudomonas aeruginosa</i> (n=11)	0	00%
<i>Proteus</i> spp. (n=03)	1	33.33%
Total (n=125)	27	21.6%

Out of total 125gram negative bacilli, 27 isolates were confirmed for Amp C β -lactamase production by Amp C disk test (21.6%). Minimum Inhibitory Concentration (MIC) was tested in these isolates by Hi-comb MIC strips.

Table 5: Minimum Inhibitory Concentration (MIC) of ceftazidime in Amp C producers

MIC of Ceftazidime in (μ gm/ml)	Isolates of <i>E.coli</i> (n= 17)	Isolates of <i>Citrobacter</i> spp. (n=6)	Isolates of <i>Klebsiella</i> spp. (n=3)	Isolates of <i>Proteus</i> spp. (n=1)
2	-	-	-	-
4	3	1	-	-
8	-	-	-	-
16	2	1	-	-
32	3	2	-	-
64	7	1	2	-
128	1	1	1	1
256	1	-	-	-

Table 6: Sensitivity of Amp C β -lactamase producing organisms to different antibiotics

Name of bacteria	<i>E.coli</i> (n=17)	<i>Citrobacter</i> spp. (n=6)	<i>Klebsiella</i> spp.(n=3)	<i>Proteus</i> spp. (n=1)
Ceftazidime	3 (17.65%)	1(16.67%)	-	-
Ceftriaxone	2(11.76%)	-	-	-
Cefotaxime	2(11.76%)	1(16.67%)	1 (33.33%)	1(100%)
Amikacin	13(76.47%)	4(66.67%)	2(66.67%)	1(100%)
Piperacillin-tazobactam	5(29.41%)	3(50%)	1(33.33%)	-
Ceftazidime-clavuanic acid	-	-	-	-
Imipenem	16(94.12%)	5(83.33%)	3 (100%)	1 (100%)
Meropenem	16(94.12%)	6 (100%)	2(66.67%)	-
Nitrofurantoin	14(82.35%)	4(66.67%)	2(66.67%)	1 (100%)
Ciprofloxacin	12(70.59%)	3(50%)	2(66.67%)	-
Gentamicin	11(64.71%)	4 (66.67%)	1(33.33%)	1 (100%)

DISCUSSION

Urinary tract infection is the most common infection in human being. Bacteria causing UTI have become resistant to many broad-spectrum antibiotics. Indiscriminate use of antibiotics in the treatment of UTI has resulted in resistant organisms. By keeping all this in mind, the present study was carried out to find out gram-negative bacilli causing UTI and antibiotic susceptibility testing of these isolates.

In the current study, a total of 288 urine samples from suspected UTI were processed. Out of which 74 samples were culture-negative (i.e. 25.69%). From 214 culture-positive samples, 167 samples showed significant bacteriuria (78.03%). Female patients were 88 in number (52.69%) and male patients were 79 in number (47.31%). Similar results were reported by Sayd Mushtaq Ahmed, Ramkrishna Pai et al in their study, which showed 67.12% urine samples from UTI were culture positive in female patients¹⁵. Another study by K.D.Deshpande et al. in 2011 showed UTI was common in female (59.2%) in their study¹⁶. B. Shanthi et al. also showed the prevalence of UTI high among female i.e. 58.18% and 41.8% in the male in their study¹⁷. UTI is common in female due to following reasons² -1) short female urethra as compared with male 2) proximity of the female urethra to the anus and moist periurethral area 3) hormonal changes and anatomical differences 4) pregnancy predisposes to UTI².

In the present study, out of 167 samples of significant bacteriuria, 125 gram-negative bacilli (GNB) were isolated (i.e. 74.85%). Most common isolate among gram-negative bacilli was *E.coli* (83/125 i.e. 66.4%), followed by *Citrobacter* spp. (19/125 i.e. 15.2%). A study by Niranjana V and Malini A From Puducherry India, in their study, showed *E.coli* as most common isolate accounting for 56.8%¹⁸. Another study by S.Dugal et al. from Mumbai showed in his study, *E.coli* as most common isolate (80%), other isolates were *Klebsiella*

pneumoniae (16.07%), *P.aeruginosa* (2.67%), and *Proteus* spp.(0.8%)¹⁹. Sayd Mustq et al. in his study reported *E.coli* (81.80%) as a predominant organism in UTI, followed by *K.pneumoniae* 14.87%, *P.aeruginosa* 2.74%, *Citrobacter* spp. 0.59%¹⁵.

The present study showed resistance of *E.coli* isolates to 3rd generation cephalosporins like Ceftazidime, Cefotaxime, Ceftriaxone. The sensitivity of these isolates to Ceftazidime-clavulanic acid was 75.90% and resistance was 24.10%. Susceptibility of *E.coli* isolates to imipenem was 95.18%, meropenem 91.57% and piperacillin-tazobactam was 81.92%. Susceptibility of these isolates to nitrofurantoin was 80.72%, amikacin 79.51% and ciprofloxacin 74.70%. A study by Sayd Mushtaq et al.¹⁵ showed in their study, high resistance of gram-negative bacilli to cefuroxime, ceftriaxone and Ciprofloxacin. In their study, antibiotic sensitivity of *E.coli* showed high susceptibility pattern towards imipenem (98.5%), nitrofurantoin and piperacillin-tazobactam (91.5%). Another study by Niranjana V and Malini A showed *E.coli* isolates were sensitive to amikacin 82.6%, nitrofurantoin 82.1%, and imipenem 98.9%¹⁸.

The current study showed a sensitivity of *Citrobacter* isolates to amikacin 84.21%, nitrofurantoin 84.21%, imipenem 78.95% and meropenem 73.68%. In my study, these isolates showed less sensitivity to ceftazidime (52.63%), cefotaxime (57.89%) and ceftriaxone (63.16%). Also, the reduced sensitivity of these isolates was present to ceftazidime-clavulanic acid 57.89% and piperacillin-tazobactam 57.89% and gentamicin 63.15%. A study by K. D. Deshpande et al.¹⁶ from Latur showed sensitivity pattern of *Citrobacter* isolates as amikacin 74%, nitrofurantoin 77.7%, imipenem 100%. Their study also showed reduced sensitivity of these isolates to ceftazidime 40.7%, cefotaxime 37% and ceftriaxone 40.7%¹⁶. A study by Dr Durgesh Mahajan et al from Yavatmal, Maharashtra, showed a sensitivity of *Citrobacter* isolates

to amikacin 100%, nitrofurantoin 75%, imipenem 75% and gentamicin 75%¹⁹. Their study also reported reduced susceptibility of *Citrobacter* isolates to ceftazidime 50% and ciprofloxacin 50%²⁰.

The present study showed less sensitivity of *K.pneumoniae* to ceftazidime (33.33%), ceftriaxone (44.44%), cefotaxime (33.33%). These isolates also showed less sensitivity to ceftazidime-clavulanic acid (66.67%), ciprofloxacin (66.67%) and gentamicin (66.67%). Sensitivity of these isolates to meropenem (88.89%), imipenem (77.78%) and nitrofurantoin (77.78%) was good. A study by K.D. Deshpande et al showed less sensitivity of *K.pneumoniae* to ceftazidime (31.7%), ceftriaxone (33.33%), cefotaxime (35.7%)¹⁶. In their study, these isolates were 100% sensitive to imipenem¹⁶. A study by Monika Yadav et al from Manipur, India in their study showed susceptibility of *Klebsiella spp.* to imipenem (89.4%), nitrofurantoin 54.3%²¹. The study also reported resistance of these isolates to ceftazidime. Their study also reported resistance of *Proteus* isolates to ceftazidime (12/22 isolates resistant) and sensitivity to imipenem 95.4%²¹. In the present study, *Proteus* isolates were resistant to 3rd generation cephalosporins and sensitivity to imipenem was 66.67% but for meropenem was 100%. The present study showed reduced susceptibility of *Pseudomonas aeruginosa* isolates to ceftazidime (54.55%), ceftriaxone (54.55%). These isolates were sensitive to ceftazidime-clavulanic acid (72.73%), piperacillin-tazobactam (72.73%). These isolates showed less sensitivity to imipenem (18.18%) and meropenem (27.27%). This resistance of *Pseudomonas* isolates to imipenem and meropenem may be due to metallo- β -lactamase production. A study by Monika Yadav, Rohan Pal et al in their study reported susceptibility of *Pseudomonas* isolates to ceftazidime (33.33%), ceftriaxone (29.1%), piperacillin-tazobactam (66.6%), but sensitivity to imipenem was 91.6%²¹.

Indiscriminate use of antibiotics, inadequate intake of antibiotics results in the emergence of resistant organisms which increases morbidity and mortality. Antibiotic resistance is a worldwide problem. In the present study, organisms which were resistant to 3rd generation cephalosporins and ceftazidime-clavulanic acid were tested for Amp C β -lactamase production. The screening was done by cefoxitin resistance test and confirmation was done by Amp C Disk Test. In the present study, Amp C β -lactamase producing gram-negative bacilli isolated from UTI were 21.6%. MIC of these isolates ranged between 4 μ g/ml – 256 μ g/ml. Amp C producing organisms were sensitive to imipenem, meropenem and nitrofurantoin. A study by Pottahil Shinu, R. Bareja et al. showed in their study prevalence of Amp C β -lactamase production in gram-negative bacilli from UTI 21.26%²². Ephram Ibadan et al. in his study showed Amp C β -lactamase production in UTI 15.1%²³. Another study by Anandhi, Lakshmanan et al. showed Amp C production in *E.coli* isolates from urine 52.38% by disk diffusion method²⁴. One more

study by Anitha Madhavan et al. from Kerala reported Amp C β -lactamase production in UTI 41.42%²⁵.

80-85% of urinary tract infections are due to gram-negative bacilli while 15-20% are due to gram-positive bacteria²⁶. Prevalence of drug resistance of microorganisms in UTI is different in different environmental conditions²⁷. Extended-spectrum β -lactamase (ESBL) and Amp C β -lactamase producing gram-negative bacilli is a major problem in health-care. Different phenotypic and genotypic methods are used to detect ESBL and Amp C β -lactamase. In the current study, simple phenotypic methods like cefoxitin resistance test and Amp C Disk test were used. They are easy to perform and interpret. Regular reporting of Amp C β -lactamase producing organisms is useful to the clinician to select proper antibiotic.

CONCLUSION

Present study concludes gram-negative bacilli (74.85%) were common organisms responsible for urinary tract infection (UTI). *E.coli* (66.4%) was the most predominant causative agent of UTI. Resistance was noted by GNB to 3rd generation cephalosporins. Gram-negative bacilli showed susceptibility to amikacin, nitrofurantoin, imipenem and meropenem. *Pseudomonas* isolates showed resistance to imipenem and meropenem. Prevalence of Amp C β -lactamase producing GNB in UTI was 21.6%. Amp C β -lactamase producing organisms were susceptible to imipenem, meropenem and nitrofurantoin. Regular reporting of antimicrobial resistance mediated through Amp C β -lactamase producing organisms, judicious use of antibiotics, effective hand wash is very useful to prevent the emergence of antimicrobial resistance.

Acknowledgement: I am thankful to the Department of Microbiology, D. Y. Patil Medical College, Kolhapur for their support.

Source of funding: Nil

Conflict of interest: Nil

REFERENCES

1. D. R. Arora, B. Arora. Enterobacteriaceae: Escherichia, Klebsiella and Other Genera. Textbook of Microbiology 3rd edition Reprinted 2011. CBS Publishers and Distributors Pvt. Ltd. New Delhi. 33: 346-361.
2. Betty A Forbes, Daniel F. Sahem, Alice S. Weissfeld. Bailey and Scott's Diagnostic Microbiology International 12th edition. Infections of Urinary Tract. 57: 842-855.
3. J G Collee, J P Duguid, A G Fraser, B. P. Marmion, A Simmons. Laboratory strategy in the diagnosis of infective syndromes. Chapter 4. Practical Medical Microbiology 14th edition. Mackie and McCartney Printed in India 2007, Published by Elsevier, a division of Reed Elsevier India Private Ltd., New Delhi: 53-94.
4. C. P. Baveja. Textbook of Microbiology 6th edition. Enterobacteriaceae. Sirmour (H.P) 2018; 31: 251-266.

5. Epoke CO, Anyanwu GO, Opara AA. The prevalence of significant bacteriuria in diabetic patients. *Diabetic international* 2000; 10: 16-17.
6. Alemu A, Moges F, Abebe Agen. Bacterial profile and drug sensitivity pattern of urinary tract infection in pregnant women at University of Gondar Teaching Hospital, Northwest Ethiopia. *BMC Res Notes* 2012; 5:197.
7. David L., Paterson and Robert A Bonomo. Extended-spectrum β - lactamases: A Clinical Update , A Clinical Microbiological Reviews 2005; 18(4):657-86.
8. George A Jacoby. 'Amp C β - lactamases' *Clinical Microbiological Reviews*, 2009; 22(1): 161-182.
9. V. Hemlatha, M. Padma, Umasekar, Vinodh T M, Arunkumar A S. Detection of Amp C β - lactamase production in *E.coli* and *Klebsiella* by Inhibitor Based Method. *Indian J Med Res.* 2007; 126: 220-23.
10. Oladeinde B H, Omoregie R, Olley M, Anube J A. Urinary tract infections in a rural community in Nigeria. *North American Journal of Medical Sciences* 2011; 3(2): 75.
11. Clinical Laboratory Standards Institute (CLSI) Performance Standards for Antimicrobial Susceptibility Testing Eighteenth informational supplement: M-100-S-2008, 18: 28.
12. Gunjan Gupta, Vibhor Tak, Purva Mathur. Detection of Amp C β - lactamases in Gram-Negative Bacteria. *Journal of Laboratory Physicians* Jan-June 2014; 6(1): 1-6.
13. Parul Sinha, Rajani Sharma, Suman Rishi, Raman Sharma, Smita Sood, Deepali Pathak. Prevalence of Extended-Spectrum β - lactamase and Amp C β - lactamase producers among *E.coli* isolates in Tertiary Care Hospital in Jaipur. *Indian Journal of Pathology and Microbiology* 2008; 51(3): 367-369.
14. Dr. B.N. Harish, Mrs Parveen, Dr Ira Praharaj, Dr.Vithiya, Mrs.S.Kavitha. Detection of ESBLs and detection of carbapenemases and Amp C β - lactamases. VIII National Workshop on simple diagnostic methods in Clinical Microbiology JIPMER Pudducherry , 2009, 81-88.
15. Sayd Mustaq Ahmed, Ramkrishna Pai, Jakribettu, Shaniya Koyakutty, Arya B, Shakira VPA. Urinary Tract Infections – An overview of the Prevalence and the Antibigram of Gram Negative Uropathogens in A Tertiary Care Centre in North Kerala, India. *Journal of Clinical and Diagnostic Research* 2012; 6(7): 1192-1195.
16. K.D. Deshpande, A.P. Pichare, N M Suryavanshi, M.S. Davane. Antibigram of Gram-Negative Uropathogens In Hospitalized Patients. *International Journal of Recent Trends in Science And Technology*, 2011; 1(2): pp56-60.
17. B.Shanthi, R. Selvi, A. Madhumathy. Antimicrobial susceptibility pattern of *E.coli* from Patients With Urinary Tract Infection in Tertiary Care Hospital. *Int. J. Curr. Microbiol. App. Sci.* 2018; 7(1): 289-294.
18. Niranjana V, Malini A. Antimicrobial Resistance Pattern in *Escherichia coli* Causing Urinary Tract Infection among Inpatients. *Indian J Med Res* 2014; 139: pp 945-948
19. S. Dugal, H. Purohit. Antimicrobial Susceptibility Profile and Detection of Extended Spectrum β - lactamase Production in gram-negative uropathogens. *International Journal of Pharmacy and Pharmaceutical Sciences* 2013; 5(4): 434-438.
20. Durgesh Mahajan, Pragati Bulle. Microbiological Profile of Bacterial Isolates Causing Urinary Tract Infection in Tertiary Care Hospital. *Journal of Medical and Dental Sciences* 2016; 15(9): 145-149.
21. Monika Yadav, Rohan Pal, Shan Damrolien, Sulochana D., Khumanthem. Microbial Spectrum of Urinary Tract Infections and it's Antibigram in Tertiary Care Hospital. *International Journal of Research in Medical Sciences* 2017; 5(6): 2718-2722.
22. Pottahil Shinu, Rajesh Bareja, M.Goyal, V.A Singh, P. Mehrishi, Monika Bansal, Vinodkumar Narang et al. Extended-spectrum β - lactamase Production Among Gram-negative Bacilli Isolates Obtained from Urinary Tract Infections and Wound Infections. *Indian Journal of Clinical Practice* 2014; 24(11): 1019-1026.
23. Ephram Jbadin, R. Omoregie I. O., Idahosa Onaiwu Enabulele. Prevalence of Amp C β - lactamase and Metallo- β - lactamase enzymes from patients with urinary tract infections in Benin City, Nigeria. *NZ Med Lab Sci.* 2018; 72: 11-16.
24. Anandhi Lakshmanan, D. Thirunavukkarasu, T. Umaarasu and S. Rajesh. Assessment of Amp C β - lactamase Production by Various Methods in Urinary Isolates Of *E.coli* from a Tertiary Care Teaching Hospital. *Int. J. Curr. Microbiol. App.Sci* 2016; 5(11): 388-395.
25. Anitha Madhavan, Jaylaxmi. The occurrence of extended-spectrum β - lactamase, Amp C β - lactamase and MB lactamase producers among multidrug-resistant *Enterobacteriaceae* causing Urinary Tract Infections In Tertiary Care Hospital. *Journal of Academy of Clinical Microbiology* 2016; 18(2): 80-85.
26. Gul N, Mujahid T Y., Ahmed S. Isolation, Identification and Antibiotic resistance Profile of Indigenous Bacterial Isolates from Urinary Tract Infection patients. *Pak J Biol Sci* 2004; 7(12): 2051-2054.
27. Gupta K, Hootan TM, Stamm WE. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. *Ann Intern Med* 2001; 135(1): 41-50.